Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
MREO Stock Chart & Stats
$0.39
-$0.02(-0.40%)
At close: 4:00 PM EST
$0.39
-$0.02(-0.40%)
Day’s Range― - ―
52-Week Range$0.20 - $3.05
Previous CloseN/A
Volume219.93K
Average Volume (3M)2.51M
Market Cap
$61.41M
Enterprise Value$13.33M
Total Cash (Recent Filing)$48.70M
Total Debt (Recent Filing)$397.00K
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Apr 01, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding159,131,700
10 Day Avg. Volume1,448,441
30 Day Avg. Volume2,505,364
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)8.49
Price to Sales (P/S)0.00
P/FCF Ratio-15.44
Enterprise Value/Market Cap0.22
Enterprise Value/Revenue26.66
Enterprise Value/Gross Profit139.52
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$1.75Price Target Upside348.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$25.10M
Bulls Say, Bears Say
Bulls Say
Clinical BenefitPatient-reported reductions in bone pain and improvements in comfort, activity, and daily functioning among pediatric and teen patients indicate meaningful functional benefits beyond measured bone density gains.
Financial Runway And PartnershipsManagement's decision to reduce and delay pre-commercial activity, together with cash resources intended to provide runway into 2027 and ongoing partner discussions for the alvelestat program, preserves strategic flexibility to advance key programs.
Regulatory PathwayStatistically significant increases in bone mineral density in both pivotal trials, combined with FDA endorsement of BMD as a valid surrogate endpoint in osteogenic disorders, may provide a viable regulatory route for approval despite fracture outcomes.
Bears Say
Primary Endpoint FailureThe ORBIT and COSMIC phase 3 trials did not meet the primary endpoint of reducing annualized fracture rates, undermining the central efficacy claim for setrusumab.
Trial Interpretation And Confounding FactorsAn unexpectedly low placebo fracture rate and increased physical activity among treated patients likely masked treatment effects and complicated interpretation of the trials' efficacy results.
Valuation And Market SentimentHeightened regulatory uncertainty and a lowered probability of program success have prompted analyst downgrades and reduced price targets, increasing the risk of near-term downside and share trading near cash value.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $0.20 and its highest was $3.05 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is $61.41M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Apr 01, 2026 which is in 16 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Nov 10, 2025. The company reported -$0.01 earnings per share for the quarter, missing the consensus estimate of -$0.006 by -$0.004.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,131,700 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.01 in its last earnings report, missing expectations of -$0.006. Following the earnings report the stock price went up 5.65%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in MREO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.75 (348.72% Upside)
$1.75 (348.72% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 517.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.56%
12-Months-Change
Fundamentals
Return on Equity
-74.85%
Trailing 12-Months
Asset Growth
-39.60%
Trailing 12-Months
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Stock 12 Month Forecast
Average Price Target
$1.75
▲(348.72% Upside)
Technical Analysis
Ownership Overview
0.79%
Insiders
0.77% Mutual Funds
13.07% Other Institutional Investors
85.07% Public Companies and
Individual Investors